SCHEMBL2301176

SCHEMBL2301176

CCCCc1ccc(NS(=O)(=O)c2ccc(N3CCNC3=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.61
FFAR4 Q5NUL3 1/20 0.61
LMNA P02545 2/20 0.59
TP53 P04637 2/20 0.59
DRD2 P14416 8/20 0.54
DRD3 P35462 8/20 0.54
HTR6 P50406 5/20 0.54
HTR2A P28223 4/20 0.54
HTR2C P28335 4/20 0.54
MLNR O43193 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
CYP2D6 P10635 1/20 0.54
HSP90AA1 P07900 1/20 0.53
HSP90AB1 P08238 1/20 0.53
KCNH2 Q12809 2/20 0.53
MAPT P10636 1/20 0.52
GHSR Q92847 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2301954 0.97 FFAR1 (0.57) FFAR1FFAR4LMNATP53DRD2
SCHEMBL2300361 0.96 FFAR1 (0.56) FFAR1FFAR4LMNATP53DRD2
SCHEMBL2357330 0.89 ALDH1A1 (0.61) FFAR4LMNATP53HTR6MAPT
SCHEMBL2299468 0.86 SMN1; SMN2 (0.56) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12353790 0.84 ALDH1A1 (0.49) LMNAHTR6MAPTGHSRALDH1A1
SCHEMBL2305007 0.83 SMN1; SMN2 (0.53) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL2301965 0.82 ALDH1A1 (0.60) LMNAMAPTALDH1A1
SCHEMBL14217356 0.81 ALDH1A1 (0.54) LMNATP53HTR6MAPTALDH1A1
SCHEMBL2304028 0.81 ALDH1A1 (0.69) LMNAHTR6MAPTALDH1A1ADRB2
SCHEMBL12353712 0.81 MEN1 (0.45) LMNAHTR6MAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 FFAR1 2668/4885FFAR4 3236/4885LMNA 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.